Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-023867
Filing Date
2024-06-14
Accepted
2024-06-14 16:10:39
Documents
62
Period of Report
2024-04-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 886385
2 ex31-1.htm EX-31.1 18189
3 ex31-2.htm EX-31.2 17996
4 ex32-1.htm EX-32.1 7080
5 ex32-2.htm EX-32.2 7634
  Complete submission text file 0001493152-24-023867.txt   4864290

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE bctx-20240430.xsd EX-101.SCH 33306
7 XBRL CALCULATION FILE bctx-20240430_cal.xml EX-101.CAL 40150
8 XBRL DEFINITION FILE bctx-20240430_def.xml EX-101.DEF 192543
9 XBRL LABEL FILE bctx-20240430_lab.xml EX-101.LAB 276181
10 XBRL PRESENTATION FILE bctx-20240430_pre.xml EX-101.PRE 244662
66 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 830535
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 10-Q | Act: 34 | File No.: 001-40101 | Film No.: 241044852
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)